) XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE ... Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million.
Avadel Pharmaceuticals Reports SecondQuarter 2025 Financial Results and Raises 2025 Revenue Guidance ... -- Raises 2025 full year revenue guidance to $265 - $275 million -- ... · Raising 2025 full year revenue guidance to $265- $275 million.
Raises Full Year 2025 Revenue Guidance ... for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025.
● Raising full year 2025 revenue ... 2025 Guidance ● Raising full year 2025 net revenues guidance to $39.5 - $40.5 million, representing growth of 18% - 20%, from prior range of $38.5 - $39.5 million.
) PROCEPT BioRobotics Reports SecondQuarter 2025 Financial Results and Increases 2025 Revenue Guidance ... •Increased fiscal year 2025 total revenue guidance to $325.5 million, an increase of 45% compared to the prior year period in 2024.
On the other hand, next quarter’s revenue guidance of $445 million was less impressive, coming in 0.6% below analysts’ estimates ... On the other hand, its revenue and EBITDA guidance for next quarter fell slightly short of Wall Street’s estimates.
On the other hand, next quarter’s revenue guidance of $775 million was less impressive, coming in 0.9% below analysts’ estimates ... Its EPS missed and its revenue guidance for next quarter fell slightly short of Wall Street’s estimates.
$703 million vs analyst estimates of $662.1 million (25.6% margin, 6.2% beat)Revenue Guidance for Q3 CY2025 is $2.75 billion at the midpoint, above analyst estimates of $2.69 billionOperating Margin.